Targeting MET and EGFR in NSCLC-what can we learn from the recently reported phase III trial of onartuzumab in combination with erlotinib in advanced non-small cell lung cancer? (Q43195857)
Jump to navigation
Jump to search
scientific article published in December 2014
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Targeting MET and EGFR in NSCLC-what can we learn from the recently reported phase III trial of onartuzumab in combination with erlotinib in advanced non-small cell lung cancer? |
scientific article published in December 2014 |
Statements
Targeting MET and EGFR in NSCLC-what can we learn from the recently reported phase III trial of onartuzumab in combination with erlotinib in advanced non-small cell lung cancer? (English)
Michail Charakidis